Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note released on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

NASDAQ BCLI opened at $1.86 on Friday. The firm has a market capitalization of $10.60 million, a price-to-earnings ratio of -0.39 and a beta of 0.26. The company’s fifty day moving average is $1.99 and its two-hundred day moving average is $2.67. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.